Financial Performance - Net sales for the third quarter were $347.8 million, an increase of $84.6 million, or 32% year-over-year[3] - Adjusted EBITDA reached $54.9 million, an increase of $25.2 million, or 85% compared to the same quarter last year[18] - Net income for the quarter was $20.9 million, up $12.5 million from $8.4 million in the prior year[17] - The company reported a gross profit of $104.6 million, an increase of $25.0 million, or 31% year-over-year[9] - Operating income increased by 68% to $33.5 million for the three months ended March 31, 2025, up from $19.9 million in the same period of 2024[34] - Adjusted net income for the nine months ended March 31, 2025, reached $61.7 million, up $30.0 million (95%) from $31.7 million in the prior year[41] Segment Performance - Animal Health segment sales increased by 42% to $258.4 million, with MFA & Other product sales up 68% due to the acquisition of the Zoetis MFA portfolio[5] - The Animal Health segment reported net sales of $258.4 million for the three months ended March 31, 2025, a 42% increase from $181.3 million in the prior year[37] Guidance and Projections - The company updated its fiscal year 2025 guidance, projecting net sales between $1.26 billion and $1.29 billion, representing a 25% growth[25] Earnings and Expenses - Adjusted diluted earnings per share for the quarter were $0.63, an increase of $0.32 compared to the prior year[21] - Selling, general and administrative expenses increased by $11.4 million, or 19%, primarily due to costs associated with Phibro Forward initiatives and increased headcount from the acquisition[11] - Adjusted selling, general and administrative expenses for the three months ended March 31, 2025, were $67.2 million, a 15% increase from $58.5 million in the prior year[41] Tax and Interest - The effective income tax rate for the quarter was 29.7%, down from 35.0% in the prior year, primarily due to higher pretax earnings[15] - The effective tax rate decreased to 29.7% for the three months ended March 31, 2025, down from 35.0% in the same period of 2024[34] - Interest expense increased to $9.4 million for the three months ended March 31, 2025, compared to $4.6 million in the prior year, reflecting an increase of 104%[34] - The adjusted effective tax rate for the three months ended March 31, 2025, was 25.7%, down from 30.8% in the same period of 2024[42] Cash Flow and Currency - Free cash flow for the twelve months ended March 31, 2025, was $49.1 million[25] - The company reported a 60% decrease in foreign currency losses, with net losses of $5.5 million for the three months ended March 31, 2025, compared to gains of $2.4 million in the same period of 2024[34] - Foreign currency losses for the three months ended March 31, 2025, were $(5.5) million, a decrease of $7.9 million compared to a gain of $2.4 million in the same period of 2024[41] Strategic Initiatives - The company is focused on the Phibro Forward initiative, which aims to unlock additional revenue growth and cost savings, including $5.3 million for non-cash asset write-offs related to the closure of an immaterial business[39] Adjusted Metrics - Adjusted gross profit for the three months ended March 31, 2025, was $111.2 million, reflecting a 36% increase from $81.5 million in the same period of 2024[41] - Adjusted income before income taxes for the three months ended March 31, 2025, was $34.6 million, an increase of $16.2 million (88%) compared to $18.4 million in the same period of 2024[41] - Adjusted cost of goods sold for the three months ended March 31, 2025, was $236.6 million, a 30% increase from $181.7 million in the same period of 2024[41] - Adjusted net income per share diluted for the three months ended March 31, 2025, was $0.63, up $0.32 (103%) from $0.31 in the same period of 2024[41] Acquisition Costs - The company reported a significant increase in acquisition-related costs, with transaction costs rising to $12.9 million for the nine months ended March 31, 2025, compared to $0.5 million in the prior year[41]

Financial Performance - Net sales for the three months ended March 31, 2025, were $347.8 million, a 32% increase from $263.2 million in the same period of 2024[120] - Gross profit for the three months ended March 31, 2025, was $104.6 million, reflecting a 31% increase compared to $79.6 million in the prior year[120] - Operating income for the three months ended March 31, 2025, was $33.5 million, a 68% increase from $19.9 million in the same period of 2024[120] - Net income for the three months ended March 31, 2025, was $20.9 million, compared to $8.4 million in the same period of 2024, marking a significant increase[120] - Adjusted EBITDA for the three months ended March 31, 2025, was $54.9 million, an increase of $25.2 million or 85% compared to the same period in 2024[123] - Net sales for the nine months ended March 31, 2025, were $917.5 million, an increase of $173.0 million or 23% compared to the same period in 2024[141] - Net income for the nine months ended March 31, 2025, was $31.0 million, compared to $1.7 million for the same period in 2024[154] - Adjusted net income for the nine months ended March 31, 2025, was $61.7 million, a 95% increase from $31.7 million in 2024[156] - Adjusted diluted earnings per share (EPS) for the nine months ended March 31, 2025, was $1.52, up 95% from $0.78 in 2024[158] Expenses and Costs - Selling, general and administrative expenses (SG&A) for the three months ended March 31, 2025, were $71.1 million, an increase of $11.4 million or 19% compared to the same period in 2024[134] - Selling, general and administrative expenses (SG&A) totaled $213.2 million, an increase of $22.1 million, or 12%[148] - Interest expense for the three months ended March 31, 2025, was $9.4 million, an increase of 88% from $4.6 million in the same period of 2024[120] - Interest expense, net increased to $26.0 million, up $12.2 million, or 88%, due to higher debt levels from financing acquisitions[150] Taxation - The effective tax rate for the three months ended March 31, 2025, was 29.7%, down from 35.0% in the same period of 2024[120] - The effective income tax rate for the nine months ended March 31, 2025, was 29.7%, down from 63.1% in 2024, primarily due to higher pretax earnings[152] Acquisitions and Investments - The company completed the acquisition of Zoetis's medicated feed additive portfolio for approximately $302.9 million, which generated $407.6 million in revenue in 2023[108] - Animal Health segment net sales increased by $77.0 million or 42%, driven by $73.4 million from the Zoetis MFA portfolio acquired on October 31, 2024[127] - Investing activities used $281.7 million in net cash, primarily due to the acquisition purchase price of $291.9 million and capital expenditures of $25.2 million[161] Cash Flow and Liquidity - For the nine months ended March 31, 2025, operating activities provided $58.9 million in net cash, with net income adjusted for non-cash items totaling $66.2 million[160] - Financing activities generated $214.9 million in net cash, reflecting $300.0 million from debt refinancing and $350.0 million from term loan borrowings for the acquisition[162] - As of March 31, 2025, cash and cash equivalents and short-term investments totaled $70.4 million, with working capital at $455.4 million and a current assets to current liabilities ratio of 2.82:1[164] - The company expects adequate liquidity for at least the next twelve months, considering macroeconomic conditions and potential risks[163] Risks and Forward-Looking Statements - Forward-looking statements indicate potential risks including competition, regulatory actions, and economic conditions that may impact future performance[179] - The company faces risks related to product approval, R&D, acquisition, and licensing efforts that may not generate new products[183] - The company is dependent on its Israeli and Brazilian operations, which may impact overall performance[183] - The company has a substantial level of indebtedness and related debt-service obligations that could affect financial stability[183] - The company utilizes foreign currency contracts and interest rate swaps to hedge exposure to market risks, but does not eliminate the effects of changing market conditions[184] - As of the report date, there were no material changes in the company's financial market risks from those disclosed in the Annual Report[185] Dividends - The company declared a cash dividend of $0.12 per share on Class A and Class B common stock, payable on June 25, 2025[165]

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that t ...

Phibro Animal Health (PAHC) has been beaten down lately with too much selling pressure. While the stock has lost 22.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscilla ...

Phibro Animal Health (PAHC) has been on a downward spiral lately with significant selling pressure. After declining 13.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently ...

Phibro Animal Health (PAHC) currently boasts an attractive valuation, with a forward price-to-earnings (P/E) multiple of 10.41X, well below the five-year industry average of 21.78X and its median of 13.54X.The company, known for its animal health products, also trades at a more attractive valuation than industry peers IDEXX Laboratories (IDXX) and Neogen (NEOG) , which carry higher P/E multiples of 33.93X and 15.80X, respectively. The stock’s appeal is further reinforced by its Value Score of A.Price-to-Ear ...

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnin ...

Phibro Animal Health (PAHC) shares have climbed 87.5% in the past year, showcasing impressive momentum. This has outpaced the industry’s 10.4% growth and the S&P 500 Composite’s 13.8% gain.Sporting a Zacks Rank #1 (Strong Buy) at present, the renowned animal health and mineral nutrition company is gaining from the strength of its diversified portfolio across all three segments. The prospering Vaccine business and strong potential in the extensive overseas market instill optimism in the stock. Headquartered ...

It has been about a month since the last earnings report for Phibro Animal Health (PAHC) . Shares have lost about 5.2% in that time frame, outperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Phibro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. PAHC Q2 Earnings & Revenues Beat, Margins ...